Martin D. Meglasson
Keine laufenden Positionen mehr
Profil
Dr. Martin D.
Meglasson is Chief Scientific Officer & Vice President at Bellerophon Therapeutics, Inc.
Dr. Meglasson was previously employed as Chief Scientific Officer by Ikaria, Inc., Vice President-Discovery Research by Ligand Pharmaceuticals, Inc., a Director-Preclinical Pharmacology by Pharmacia, Inc., and a Director-Endocrine & Metabolic Research by Pharmacia & Upjohn, Inc.
He received his doctorate degree from the University of Houston.
Ehemalige bekannte Positionen von Martin D. Meglasson
Unternehmen | Position | Ende |
---|---|---|
IKARIA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2014 |
LIGAND PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 23.07.2010 |
Pharmacia, Inc. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2003 |
Pharmacia & Upjohn, Inc. | Corporate Officer/Principal | 01.01.1998 |
BELLEROPHON THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Martin D. Meglasson
University of Houston | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
BELLEROPHON THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Pharmacia & Upjohn, Inc. | Health Technology |
Pharmacia, Inc. | |
Ikaria, Inc.
Ikaria, Inc. BiotechnologyHealth Technology Ikaria, Inc. operates as a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to meet the medical needs of critically ill patients. It offers INOMAX for inhalation, which is used to treat newborns suffering from hypoxic respiratory failure, and is making a major impact on the critical care environment. The company was founded on August 18, 2006 and is headquartered in Clinton, NJ. | Health Technology |